Immunocore's $115.9 Million Q2 Raises the Bar-Now It Has to Prove KIMMTRAK Can Grow Again

KIMMTRAK revenue remains strong, but growth deceleration is the real signal

KIMMTRAK net revenues of $115.9 million in Q2 2026 show that commercial demand is still solid, but 30% year-over-year growth in Q2 2025 highlights how much the growth pace has slowed. For investors, that deceleration matters more than the headline total because it raises the importance of the next catalysts, including the May 31, 2026 brenetafusp data presentation.

If the next data read is constructive, this slowdown may look more like a temporary pause than a structural problem. If not, investors will be more likely to question how much further KIMMTRAK revenue can expand.

The bull case depends on a rebound, not just a strong base

The optimistic read is straightforward: KIMMTRAK still has demonstrated real-world value, and Immunocore still has the resources and trial pathway to advance the next step. The company ended the quarter with cash, cash equivalents and marketable securities of $880 million as of June 30, 2026, and enrollment in Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma nearing the target of 540 patients, leaving room for expansion data as early as the end of 2026.

The skeptical read is equally clear. When growth slows from 30% year-over-year growth in Q2 2025 to 18% year-over-year, the market tends to stop treating the asset as if it is still in the early adoption phase. That does not prove KIMMTRAK has hit a ceiling, but it does raise the burden of proof on the next data.

The key question now is whether this was the bottom of the growth curve or simply the start of a flatter plateau.